Related Experiment Video
Updated: Mar 15, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
[Type 2 diabetes mellitus and heart failure]
Insights
Type 2 diabetes mellitus significantly increases heart failure risk. Some diabetes drugs raise this risk, but empagliflozin showed a considerable reduction in a recent trial.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is linked to increased heart failure risk.
- Mechanisms include coronary heart disease, hypertension, aortic stiffness, arrhythmias, renal failure, and diabetic cardiomyopathy.
- Certain diabetes medications may also induce heart failure.
Purpose of the Study:
- To review evidence on the benefits and harms of diabetes treatments concerning heart failure.
- To analyze recent randomized trial results.
Main Methods:
- Review of current evidence on diabetes treatments and heart failure.
- Analysis of data from recent randomized controlled trials.
Main Results:
- Sulfonylureas, glizatones, and some DPP-4 inhibitors are associated with increased heart failure risk.
- Empagliflozin demonstrated a significant reduction in heart failure risk in the EMPA-REG OUTCOME trial.
Conclusions:
- Diabetes treatment strategies must consider heart failure risks and benefits.
- Empagliflozin shows promise in mitigating heart failure risk in T2DM patients.
Unlabelled:
Type 2 diabetes mellitus is associated with a substantial increase in the risk of development of heart failure. The mechanisms causing this complication are complex and include coronary heart disease, myocardial changes induced by hypertension, increased aortic stiffness, arrhythmias, renal failure and last but not least by direct metabolic alterations causing diabetic cardiomyopathy. The heart failure could be induced by several drugs used for diabetes therapy. This review debates the current evidence of harms and benefits of diabetes treatment related to heart failure in the light of results of recent randomized trials. An increased risk of heart failure was reported with sulphonylureas, glizatones and some DPP4 inhibitors. In contrast a considerable risk reduction was demonstrated in the EMPA-REG OUTCOME trial using empagliflozin.
Key Words:
aortic stiffness - arrhythmias - coronary heart disease - diabetes treatment - diabetic cardiomyopathy - hypertension - type 2 diabetes mellitus.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Heart Failure IV: Classification and Diagnostic Evaluation

